[CAS NO. 379270-38-9]  Tenofoviralafenamidefumarate

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [379270-38-9]

Catalog
HY-15232A
Brand
MCE
CAS
379270-38-9

DESCRIPTION [379270-38-9]

Overview

MDLMFCD28167823
Molecular Weight592.54
Molecular FormulaC25H33N6O9P
SMILESNC1=NC=NC2=C1N=CN2C[C@@H](C)OC[P@](OC3=CC=CC=C3)(N[C@@H](C)C(OC(C)C)=O)=O.O=C(O)/C=C/C(O)=O

For research use only. We do not sell to patients.


Summary

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor .


IC50 & Target

HIV-1

HIV-2


In Vitro

Tenofovir alafenamide fumarate (GS-7340 fumarate) antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC 50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC 50 s range from 0.1 to 12 nM, with a mean EC 50 of 3.5 nM compared to a mean EC 50 of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC 50 s are 1.8 nM for TAF and 6.4 nM for AZT [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT04483674 Anna Cruceta|Fundacion Clinic per a la Recerca Biomédica
HIV Primary Infection
December 4, 2020 Phase 2
NCT03753074 Young-Suk Lim|Samsung Medical Center|Kyunghee University Medical Center|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|Seoul National University Hospital|Ulsan University Hospital|Konkuk University Medical Center|Kyungpook National University Hospital|Korea University Guro Hospital|Seoul St. Mary´s Hospital|Kaohsiung Medical University|Chang Gung Memorial Hospital|E-DA Hospital|Taitung Mackay Memorial Hospital|National Cheng-Kung University Hospital|Chi Mei Medical Hospital|Chiayi Christian Hospital|St. Martin De Porress Hospital|Dalin Tzu Chi General Hospital|Taichung Veterans General Hospital|China Medical University Hospital|Asan Medical Center
Chronic Hepatitis b
February 18, 2019 Phase 4
NCT02957864 Erasmus Medical Center|Gilead Sciences
Renal Insufficiency,Chronic|Hiv|Therapeutic Agent Toxicity
October 2016 Phase 4

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)


Solvent & Solubility

In Vitro:

DMSO : ≥ 36 mg/mL ( 60.76 mM )

H 2 O : ≥ 25 mg/mL ( 42.19 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6876 mL 8.4382 mL 16.8765 mL
5 mM 0.3375 mL 1.6876 mL 3.3753 mL
10 mM 0.1688 mL 0.8438 mL 1.6876 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 6.67 mg/mL (11.26 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

* All of the co-solvents are available by MCE.